ÂÜÀòÂÒÂ×

Mikko Mannerkoski has an extensive work experience spanning multiple industries and roles. In 1997, they joined Mandatum & Co Investment Bank as a Partner and Deputy to the CEO, where they worked until 2003. In the same year, they founded Aventum Partners, a company they ran as Founder until December 2020. From 2010, Mannerkoski also founded Glykos Finland and served as its Founder. In 2012, they founded Tenboron Oy and served as its Founder as well. In 2016, they founded Neutron Therapeutics, Inc., and in 2019, they founded Rappta Therapeutics, both as a Founder. More recently, in 2021, they became the Chairman of Aranda Pharma Ltd. Lastly, in 2022, they joined KCL as an Investor and Board Director.

Mikko Mannerkoski enrolled in Teknillinen Korkeakoulu-Tekniska Högskolan in 1990 and completed their M.Sc. degree in Engineering in 1995. Following that, they pursued a one-year MBA program in Finance at Helsingin Kauppakorkeakoulu, which they completed in 1996. It is unclear when Mikko enrolled in the University of Michigan - Stephen M. Ross School of Business, as no specific start or end year is provided. The degree and field of study for this particular institution are also unspecified.